- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Top 5 Q&As of 2023
Pharm Exec spent the year speaking with some of the most interesting professionals from the life sciences industry.
Q&A: How Does a ‘Never Enough’ Achievement Culture Impact Your Workforce’s Morale? Planning for 2024 With Journalist and Author Jennifer Breheny Wallace
Jennifer Breheny Wallace, award-winning journalist and author, notes that C-Suite leaders should understand the financial risks of not taking action to address workplace burnout in 2024.
Reacting to Trends: Q&A With Leslie Orne, CEO of Trinity Life Sciences
Orne discusses the forces impacting the life sciences market and how companies are reacting.
Q&A With Kevin O'Neill, president and CEO of GE HealthCare, Pharmaceutical Diagnostics
O'Neill discusses the company's place in the global market and recent advancements to improve the patient experience.
The Changing Prescriber Communications Dynamic: Q&A with Caleb Costa, Chief Customer Officer at InCrowd
Explore the changing dynamics of healthcare professionals' communication preferences in a post-pandemic world, as Pharm Exec's Fran Pollaro has a no frills discussion about InCrowd's latest insights with chief customer officer Caleb Costa.
Threads, the Twitter Competitor's Impact on Pharma Marketing: Q&A with Justin Chase
An insightful discussion about how Meta's newest social media platform, Threads, is quickly adding another facet to the digital landscape for pharma marketers.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
